[2] Maria Mavris, Andrea Furia Helms, Nathalie Bere. Engaging patients in medicines regulation: a tale of two agencies. Nature Reviews Drug Discovery, Sept 30, 2019. doi: 10.1038/d41573-019-00164-y
[3] FDA. FDA Basics. Retrieved Oct 3, 2019 from https://www.fda.gov/about-fda/transparency/fda-basics
[4] FDA. Fda Patient Representative Program. Retrieved Oct 3, 2019 from https://www.fda.gov/patients/learn-about-fda-patient-engagement/about-fda-patient-representative-program
[5] EMA. EMA Basics. Retrieved Oct 3, 2019 from https://www.youtube.com/watch?v=UbWp2AYi_xM&feature=player_detailpage&list=PL7K5dNgKnawbH-EkoRxEGZ3iFD0ZMweCZ
[6] FDA. FDA rare disease listening sessions. Retrieved Oct 3, 2019 from https://www.fda.gov/patients/learn-about-fda-patient-engagement/patient-listening-sessions
[7] EMA. Patients' and Consumers' Working Party. Retrieved Oct 3, 2019 from https://www.ema.europa.eu/en/committees/working-parties-other-groups/chmp/patients-consumers-working-party
[8] FDA. Patient Engagement Collaborative. Retrieved Oct 3, 2019 from https://www.fda.gov/patients/learn-about-fda-patient-engagement/patient-engagement-collaborative
[9] FDA. For Patients. Retrieved Oct 3, 2019 from https://www.fda.gov/patients
[10] EMA. Committees. Retrieved Oct 3, 2019 from https://www.ema.europa.eu/en/committees/how-committees-work
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。▽关注【药明康德】微信公众号